Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03940950 · ClinicalTrials.gov registry record · Phase 1
Intra-articular Transplantation of Autologous Adipose Derived Stromal Vascular Faction (SVF) for Treatment of Osteoarthritis of the Knee
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT03940950: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT03940950 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03940950, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
Researchers are trying to determine the safety and feasibility of autologous, adipose derived stromal vascular fraction injections in the treatment of knee osteoarthritis
Primary Outcome
Number of adverse events reported
Interventions
- DRUG Placebo
- BIOLOGICAL Autologous Adipose-Derived SVF (Stromal Vascular Fraction)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2019-07-02 |
| Est. Completion | 2025-05-23 |
| Phase | Phase 1 |
What the finished NCT03940950 record still lists
NCT03940950 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03940950 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03940950 about?
NCT03940950 is a clinical study titled "Intra-articular Transplantation of Autologous Adipose Derived Stromal Vascular Faction (SVF) for Treatment of Osteoarthritis of the Knee". Researchers are trying to determine the safety and feasibility of autologous, adipose derived stromal vascular fraction injections in the treatment of knee osteoarthritis
What is the current status of trial NCT03940950?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2019-07-02. Estimated completion is 2025-05-23.
What interventions are being tested in trial NCT03940950?
The interventions under investigation include: Placebo (DRUG), Autologous Adipose-Derived SVF (Stromal Vascular Fraction) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03940950?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03940950's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI